Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pushengkang (also known as Picika) is an oral solution formulation containing triterpenoid saponins, specifically CKL-A03, as its active component. Developed by Beijing Deyitang Health Technology and CK Biotech Laboratory (Changjiang Biochemical Technology Research Institute), Pushengkang is being investigated for the treatment of HIV infection (Acquired Immunodeficiency Syndrome). The drug has undergone Phase I clinical trials in China to evaluate its safety, tolerability, and pharmacokinetics in healthy adult volunteers, including studies assessing the impact of food intake on its absorption.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pushengkang.